[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100591413":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":25,"centralContacts":25,"locations":31,"responsibleParty":91,"collaborators":93,"id":99,"slug":100,"hasResults":101,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":25,"eligibilityCriteria":105,"healthyVolunteers":101,"sex":106,"minAge":107,"maxAge":25,"enrollmentInfo":108,"targetDuration":25,"studyType":111,"phases":112,"briefSummary":114,"conditions":115,"keywords":117,"overallStatus":34,"whyStopped":25,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":131},{"fullName":5,"class":6},"Georgetown University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Usual Care Condition","ACTIVE_COMPARATOR","Patients randomized in the Usual Care Condition arm will receive a link for the American Cancer Society website on Radioactive Iodine (Radioiodine) Therapy for Thyroid Cancer as our comparison.",[13],"Behavioral: Usual Care",{"label":15,"type":16,"description":17,"interventionNames":18},"Decision Aid","EXPERIMENTAL","Patients randomized in the RAI Decision website arm will receive information about intermediate risk DTC; treatment options for intermediate risk DTC following thyroidectomy; clarification of the decision to be made (to have RAI therapy or not); risks and benefits of each treatment option, including potential side effects related to salivary gland damage, lacrimal and nasal symptoms, delay in childbearing; clarification of values and preferences around treatment options; structured guidance around communication with the healthcare team and information to support decision-making about RAI.",[19],"Behavioral: Decision Aid",[21,26],{"type":22,"name":15,"description":23,"armGroupLabels":24,"otherNames":25},"BEHAVIORAL","The study intervention is a web-based decision aid (DA) developed by the study team. The Radioactive Iodine Decisions decision aid is designed as an educational tool to help patients have information about Radioactive Iodine and encourage them to talk with their medical team about this treatment decision.",[15],null,{"type":22,"name":27,"description":11,"armGroupLabels":28,"otherNames":29},"Usual Care",[9],[30],"American Cancer Society website on Radioactive Iodine (Radioiodine) Therapy",[32,60,74],{"facility":33,"status":34,"city":35,"state":36,"zip":37,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"Lombardi Comprehensive Cancer Center","RECRUITING","Washington D.C.","District of Columbia","20007","United States","US",{"type":41,"coordinates":42},"Point",[43,44],-77.03637,38.89511,{"lat":44,"lon":43},[47,52,55,58],{"name":48,"role":49,"phone":50,"phoneExt":25,"email":51},"Lourdes M Inbar-Albo, MD,MSc. Project Director","CONTACT","202-687-3628","thyroidcancerstudy@georgetown.edu",{"name":53,"role":49,"phone":50,"phoneExt":25,"email":54},"Jacqueline Jonklaas, MD","jonklaaj@georgetown.edu",{"name":56,"role":57,"phone":25,"phoneExt":25,"email":25},"Jacqueline Jonklaas, MD, PhD, MPH","PRINCIPAL_INVESTIGATOR",{"name":59,"role":57,"phone":25,"phoneExt":25,"email":25},"Kristi D Graves, Ph.D.",{"facility":61,"status":34,"city":35,"state":36,"zip":62,"country":38,"countryCode":39,"cosmosGeoPoint":63,"geoPoint":65,"contacts":66},"MedStar Washington Hospital Center","20010",{"type":41,"coordinates":64},[43,44],{"lat":44,"lon":43},[67,71],{"name":68,"role":49,"phone":69,"phoneExt":25,"email":70},"Leila Shobab, MD","202-877-0526","Leila.Shobab@medstar.net",{"name":72,"role":73,"phone":25,"phoneExt":25,"email":25},"Leila Shobab, MD, Assistant Professor","SUB_INVESTIGATOR",{"facility":75,"status":34,"city":76,"state":77,"zip":78,"country":38,"countryCode":39,"cosmosGeoPoint":79,"geoPoint":83,"contacts":84},"Inova Health System","Falls Church","Virginia","22031",{"type":41,"coordinates":80},[81,82],-77.17109,38.88233,{"lat":82,"lon":81},[85,89],{"name":86,"role":49,"phone":87,"phoneExt":25,"email":88},"Samantha Diamond, MD","‭703-776-3574‬","Samantha.Diamond-rossi@inova.org",{"name":90,"role":73,"phone":25,"phoneExt":25,"email":25},"Samantha Diamond-Rossi, MD",{"type":92,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR",[94,97],{"name":95,"class":96},"National Institutes of Health (NIH)","NIH",{"name":98,"class":96},"National Institute of Dental and Craniofacial Research (NIDCR)","100591413","use-of-a-decision-aid-to-resolve-uncertainty-about-radioactive-iodine-treatment-in-patients-with-intermediate-risk-thyroid-cancer-100591413",false,"NCT06980103","Use of a Decision Aid to Resolve Uncertainty About Radioactive Iodine Treatment in Patients With Intermediate Risk Thyroid Cancer","Use of a Decision Aid to Resolve Uncertainty About Radioactive Iodine Treatment in Patients With Intermediate Risk Thyroid Cancer: The Radiance Trial","Inclusion Criteria:\n\n* Patients aged 18 and older\n* Patients diagnosed with intermediate risk DTC \\\u003C 6 months ago and who are making a decision about RAI treatment\n* Ability to understand the information conveyed in the informed consent form, pose questions and process answers (e.g., no cognitive impairment per direct consultation with the patient's physician), and, finally, provided informed consent to participate.\n* Participants willingness to be contacted and remain available to complete study activities throughout the duration of the study.\n\nExclusion Criteria:\n\n* Diagnosis of low risk or high risk DTC\n* Prior history of RAI\n* Clinical contraindications that prevent consideration of RAI (e.g., pregnancy, lactation, neutropenia if considering high dose of RAI)","ALL","18 Years",{"count":109,"type":110},408,"ESTIMATED","INTERVENTIONAL",[113],"NA","The goal of this study is to learn if a decision aid (DA) website helps people with thyroid cancer make informed decisions about radioactive iodine (RAI) treatment. The main questions it aims to answer are: - Does the decision aid help participants understand the risks and benefits of RAI treatment? - Does it help participants make choices that reflect what matters most to them? - How does the decision aid compare to usual care in supporting patients through this decision? Participants who have been recently diagnosed with intermediate-risk differentiated thyroid cancer (DTC) will be randomly assigned to one of two groups. One group will receive a special decision aid website. This site includes detailed information about RAI, short videos, drop-down menus with extra details, exercises to help clarify values, and tools to help patients prepare questions for their doctor. The other group will receive the American Cancer Society (ACS) website. This site gives basic information about RAI but does not include interactive tools and is not specific to intermediate-risk thyroid cancer. Follow up surveys will be sent to the participants periodically, first at the start of the study, and again at 1 week, 4 weeks, and 6 months later.\n\nResearchers will compare how the two groups differ in making informed decisions. The decision aid is meant to support, not replace, a conversation with the medical team. Doctor recommendations remain an important part of treatment decisions.",[116],"Thyroid Cancer",[15,118,116,119,120,121],"Radioactive Iodine Treatment","Intermediate Risk","Differentiated Thyroid Cancer","Intermediate risk DTC","2026-01-06",{"date":124,"type":125},"2026-01-08","ACTUAL",{"date":127,"type":125},"2025-08-06",{"date":129,"type":110},"2029-07-31",{"name":5,"class":6},3]